 |
|
In Vivo Evaluation of Brain Iron in Alzheimer Disease Using Magnetic Resonance Imaging
George Bartzokis, MD;
David Sultzer, MD;
Jeffrey Cummings, MD;
Lori E. Holt, PhD;
Darwood B. Hance, MD;
Victor W. Henderson, MD;
Jim Mintz, PhD
Arch Gen Psychiatry. 2000;57:47-53.
Background The basal ganglia contain the highest levels of iron in the brain, and postmortem studies indicate a disruption of iron metabolism in the basal ganglia of patients with Alzheimer disease (AD). Iron can catalyze free radical reactions and may contribute to oxidative damage observed in AD brains. Treatments aimed at reducing oxidative damage have offered novel ways to delay the rate of progression and could possibly defer the onset of AD. Brain iron levels were quantified in vivo using a new magnetic resonance imaging method.
Methods Thirty-one patients with AD and 68 control subjects participated in this study. A magnetic resonance imaging method was employed that quantifies the iron content of ferritin molecules (ferritin iron) with specificity through the combined use of high and low field-strength magnetic resonance imaging instruments. Three basal ganglia structures (caudate, putamen, and globus pallidus) and one comparison region (frontal lobe white matter) were evaluated.
Results Basal ganglia ferritin iron levels were significantly increased in the caudate (P = .007; effect size, 0.69) and putamen (P = .008; effect size, 0.67) of AD subjects, with a trend toward an increase in the globus pallidus (P = .13). The increased basal ganglia ferritin iron levels were not a generalized phenomenon; white matter ferritin iron levels were unchanged in patients with AD (P = .50).
Conclusions The data replicate and extend prior results and suggest that basal ganglia ferritin iron levels are increased in AD. Prospective studies are needed to evaluate whether premorbid iron levels are increased in individuals who develop AD.
From the Department of Psychiatry, University of Arkansas for Medical Sciences and the Mental Health Service, Central Arkansas Veterans Healthcare System, Little Rock (Dr Bartzokis); and the Mental Health Service, Department of Veterans Affairs Greater Los Angeles Healthcare System (Drs Bartzokis, Sultzer, and Mintz), the Departments of Psychiatry (Drs Bartzokis, Sultzer, Holt, and Mintz), Neurology (Dr Cummings), and Radiology (Dr Hance), University of California at Los Angeles, and the Department of Neurology, University of Southern California (Dr Henderson), Los Angeles.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Quantitative MR Imaging in Alzheimer Disease
Ramani et al.
Radiology 2006;241:26-44.
ABSTRACT
| FULL TEXT
Iron dysregulation and neurodegeneration: the molecular connection.
Lee et al.
Mol. Interv. 2006;6:89-97.
ABSTRACT
| FULL TEXT
Measurement of basal forebrain atrophy in Alzheimer's disease using MRI
Teipel et al.
Brain 2005;128:2626-2644.
ABSTRACT
| FULL TEXT
Differential Aging of the Human Striatum: Longitudinal Evidence
Raz et al.
Am. J. Neuroradiol. 2003;24:1849-1856.
ABSTRACT
| FULL TEXT
White Matter Structural Integrity in Healthy Aging Adults and Patients With Alzheimer Disease: A Magnetic Resonance Imaging Study
Bartzokis et al.
Arch Neurol 2003;60:393-398.
ABSTRACT
| FULL TEXT
An Iron-responsive Element Type II in the 5'-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript
Rogers et al.
J. Biol. Chem. 2002;277:45518-45528.
ABSTRACT
| FULL TEXT
Heme deficiency may be a factor in the mitochondrial and neuronal decay of aging
Atamna et al.
Proc. Natl. Acad. Sci. USA 2002;99:14807-14812.
ABSTRACT
| FULL TEXT
The Intracellular Location of Iron Regulatory Proteins Is Altered as a Function of Iron Status in Cell Cultures and Rat Brain
Pinero et al.
J. Nutr. 2001;131:2831-2836.
ABSTRACT
| FULL TEXT
Domain homologues of dopamine {beta}-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders?
Ponting
Hum Mol Genet 2001;10:1853-1858.
ABSTRACT
| FULL TEXT
|
